Health · 1 views
Investigational EGFR x HER3 therapy supports Phase III dose after lung cancer trial
An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5…
AI Summary
An investigational EGFR × HER3 antibody‑drug conjugate showed promising efficacy and a tolerable safety profile in patients with previously treated EGFR‑mutated non‑small cell lung cancer, leading researchers to select a 2.5 mg/kg dose for the global Phase III IZABRIGHT‑Lung01 registrational study.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Journalists Detail Data on Suicide, Primary Care Shortages, and Gun ViolenceContinue reading
- Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancerContinue reading
- PET/MRI improves presurgical lesion detection in pediatric epilepsyContinue reading
- Rheumatoid arthritis: Timely diagnosis and early treatment initiation are key determinants of prognosisContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow